1. Ocular Therapeutix Inc. (NASDAQ:OCUL)
Ocular Therapeutix takes the No. 1 spot because it combines clinical momentum, a large market opportunity, strong investor attention, and a potentially disruptive product candidate in wet age-related macular degeneration, or wet AMD. In biotech investing, that is the kind of combination investors look for. Wet AMD is a major eye disease market, and current treatment often requires repeated eye injections. A therapy that can maintain strong outcomes while reducing treatment burden can quickly become a serious story for doctors, patients, insurers, and investors.
The company’s leading candidate, AXPAXLI, also known as OTX-TKI, is an investigational axitinib hydrogel administered by intravitreal injection. Ocular is studying it in Phase 3 clinical trials for wet AMD and diabetic retinopathy, with the goal of improving long-term outcomes while reducing injection frequency. That “durability” angle is exactly why the story is compelling. In ophthalmology, a drug that lasts longer can matter not only because of convenience, but also because missed treatments and heavy injection schedules are real problems in chronic eye disease management.
The biggest reason OCUL ranks first is the February 2026 Phase 3 SOL-1 update. Ocular Therapeutix announced positive topline results from SOL-1, a Phase 3 superiority trial of AXPAXLI for wet AMD. The company also described the result as highlighting AXPAXLI’s durability in wet AMD, which is precisely the type of late-stage data that can separate a top small-cap biotech stock from a merely interesting one. In a market where investors are constantly searching for biotech stocks with Phase 3 catalysts, wet AMD biotech stocks, ophthalmology stocks, and high-upside small-cap healthcare stocks, OCUL has the strongest combination of timing, science, market size, and investor appeal in this ranking.
That does not mean OCUL is risk-free. No biotech stock is. The company still has to navigate regulatory review, commercial planning, competition, manufacturing, pricing, and market adoption. But among the 10 names ranked here, Ocular Therapeutix has the most compelling blend of clinical validation and large-market opportunity. That is why it deserves the No. 1 position in this list of the top 10 small-cap biotech stocks to watch today.
READ ALSO: Top 5 Best Biotech Stocks To Watch Now and Top 5 Biotech Stocks to Buy With Up to 215% Projected EPS Growth.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
